Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2025)

Arcturus Therapeutics Holdings' Operating Leases history spans 7 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 16.86% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $20.8 million, down 16.86%, while the annual FY2025 figure was $20.8 million, 16.86% down from the prior year.
  • Operating Leases reached $20.8 million in Q4 2025 per ARCT's latest filing, down from $21.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $32.2 million in Q2 2022 to a low of $4.1 million in Q1 2022.
  • Average Operating Leases over 5 years is $21.2 million, with a median of $25.5 million recorded in 2023.
  • Peak YoY movement for Operating Leases: fell 28.95% in 2022, then skyrocketed 619.42% in 2023.
  • A 5-year view of Operating Leases shows it stood at $4.5 million in 2021, then surged by 571.17% to $30.2 million in 2022, then decreased by 14.26% to $25.9 million in 2023, then decreased by 3.51% to $25.0 million in 2024, then dropped by 16.86% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Operating Leases are $20.8 million (Q4 2025), $21.9 million (Q3 2025), and $22.9 million (Q2 2025).